

North Yorkshire & York Area Prescribing Committee

Summary of decisions made regarding new product requests considered at a meeting of the Committee on the 1st February 2023.

Classification of products:

- G** **Green drug** - Can be initiated and prescribed in all care settings **○**- Second line / alternative green drug
- ASR** **Amber Specialist Recommendation drug** - Can be recommended by a specialist for initiation in primary care
- ASI** **Amber Specialist Initiation drug** – Initiated by a specialist and transferred to primary care once the patient stabilised. In some cases there may be a further restriction for use outlined - these will be defined in each case.
- ASC** **Amber Shared Care drug** - These are specialist drugs which must be initiated by the specialist, but with the potential to transfer to primary care within written and agreed shared care protocols and according to the agreed process for transfer of care
- R** **Red drug** - Drugs that should remain under the total responsibility of the specialist. Usually considered as “hospital only” drugs
- BLACK** **Not Approved** - Drugs that have been considered by the APC or other approved body and are not approved for prescribing within North Yorkshire & York.
- GREY** **Not Reviewed** - Drugs that have not been reviewed by the APC yet. This usually means that no application has been received or that an application is in progress. These drugs are not normally considered appropriate for prescribing in North Yorkshire & York.



Product	Decision			Comments/notes
	Approved	Refused	Deferred	
1) Requests deferred from previous meeting				
Nil				
2) New Requests				
Oral minoxidil for androgenic alopecia			✓	Decision: deferred a decision on the resubmission for oral minoxidil for alopecia to get clarity as to when the current North Yorkshire & York commissioning policies for hair loss will be reviewed in light of the evidence presented in this application and due the forthcoming expected NICE TA for Baricitinib for treating severe alopecia areata.
Budesonide orodispersible tablet (Jorveza® for eosinophilic oesophagitis)	✓ ASI			Jorveza is licensed for maintenance treatment as per SPC/BNF (see link below) however at the time the NICE appraisal was completed, the manufacturer only submitted an application for induction not maintenance, hence NICE have only approved for induction. Decision: approved as an AMBER SI drug for maintenance treatment as the only licensed drug for this indication and number of patients expected to be small. To remain a RED as per the relevant NICE TA for induction of remission in eosinophilic oesophagitis.

DECISION SUMMARY

Product	Decision			Comments/notes
	Approved	Refused	Deferred	
Testosterone (Testevan®)	<p>✓ ASR</p>			<p>Request for addition of an additional topical testosterone gel, Testovan, to be added to Formulary. Potential for some cost savings compared with existing brands, provides an additional brand option in the event of supply issues. The applicator may be seen as a safety advantage although may be additional plastic waste.</p> <p>Decision: approved as additional option noting that currently the cheapest topical formulation available and may offer some advantages in term of safety of administration.</p>
3) New formulations & extensions to use				
Nil this month				
5) Products considered by NICE				
<p>TA838: Slow-release potassium bicarbonate–potassium citrate for treating distal renal tubular acidosis (terminated appraisal) Commissioning: NHSE</p>	<p>✓ BLACK for this indication</p>			<p>The formulary will reflect the TAG – NHS England is the responsible commissioner.</p>
<p>TA839: Ruxolitinib for treating acute graft versus host disease refractory to corticosteroids (terminated appraisal) Commissioning: NHSE</p>	<p>✓ BLACK for this indication</p>			<p>The formulary will reflect the TAG – NHS England is the responsible commissioner.</p>
<p>TA840: Ruxolitinib for treating chronic graft versus host disease refractory to corticosteroids (terminated appraisal) Commissioning: NHSE</p>	<p>✓ BLACK for this indication</p>			<p>The formulary will reflect the TAG – NHS England is the responsible commissioner.</p>
<p>TA841: Carfilzomib with daratumumab and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal) Commissioning: NHSE</p>	<p>✓ BLACK for this indication</p>			<p>The formulary will reflect the TAG – NHS England is the responsible commissioner.</p>

DECISION SUMMARY

Product	Decision			Comments/notes
	Approved	Refused	Deferred	
TA842: Tisagenlecleucel for treating follicular lymphoma after 2 or more therapies (terminated appraisal)	✓ BLACK for this indication			The formulary will reflect the TAG – NHS England is the responsible commissioner.
TA843: Luspatercept for treating anaemia caused by beta-thalassaemia (terminated appraisal)	✓ BLACK for this indication			The formulary will reflect the TAG – NHS England is the responsible commissioner.
TA844: Luspatercept for treating anaemia caused by myelodysplastic syndromes (terminated appraisal)	✓ BLACK for this indication			The formulary will reflect the TAG – NHS England is the responsible commissioner.
TA845: Mepolizumab for treating eosinophilic granulomatosis with polyangiitis (terminated appraisal)	✓ BLACK for this indication			The formulary will reflect the TAG – NHS England is the responsible commissioner.
TA846: Mepolizumab for treating severe hypereosinophilic syndrome (terminated appraisal)	✓ BLACK for this indication			The formulary will reflect the TAG – NHS England is the responsible commissioner.
TA847: Mepolizumab for treating severe chronic rhinosinusitis with nasal polyps (terminated appraisal)	✓ BLACK for this indication			The formulary will reflect the TAG – ICS is the responsible commissioner.
TA848: Cemiplimab for untreated PD-L1-positive advanced or metastatic non-small-cell lung cancer (terminated appraisal) Commissioning: NHSE	✓ BLACK for this indication			The formulary will reflect the TAG – NHS England is the responsible commissioner.

DECISION SUMMARY

Product	Decision			Comments/notes
	Approved	Refused	Deferred	
TA849: Cabozantinib for previously treated advanced hepatocellular carcinoma Commissioning: NHSE	✓ R			The formulary will reflect the TAG – NHS England is the responsible commissioner.
TA850: Amivantamab for treating EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy	✓ BLACK for this indication			The formulary will reflect the TAG – NHS England is the responsible commissioner.
TA851: Pembrolizumab for neoadjuvant and adjuvant treatment of triple-negative early or locally advanced breast cancer	✓ R			The formulary will reflect the TAG – NHS England is the responsible commissioner.
TA852: Trifluridine–tipiracil for treating metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma after 2 or more treatments Commissioning: NHSE	✓ R			The formulary will reflect the TAG – NHS England is the responsible commissioner.
TA853: Avatrombopag for treating primary chronic immune thrombocytopenia	✓ R			The formulary will reflect the TAG – ICS is the responsible commissioner.
TA854: Esketamine nasal spray for treatment-resistant depression	✓ BLACK for this indication			The formulary will reflect the TAG – ICS is the responsible commissioner.
6) Appeals against earlier decisions by the APC				
None				
7) Miscellaneous formulary decisions by the APC				
Nil this month				

The following guidelines were presented to and approved at the February 2023 meeting of the APC:

- Vitamin D Guidance - reviewed and updated
- Dry Eyes Guideline – minor update

DECISION SUMMARY

- Upadacitinib for treating moderately to severely active ulcerative colitis – updated pathway

The following guidelines were presented to and recommended for approval to the HNY IPMOC at the February 2023 meeting of the APC:

- Nil this month.

The following shared care guidelines were presented to and approved at the February 2023 meeting of the APC:

- Nil this month.

The following documents were presented to and approved at the February 2023 meeting of the APC:

- Respiratory Formulary Chapter Review.